1Department of Pharmaceutical Sciences, Faculty of Pharmaceutical and Biological Sciences, Félix Houphouët-Boigny University, BPV34 Abidjan, Côte d’Ivoire
2Directorate of Pharmaceutical Activity, Ministry of Health, Public Hygiene and Universal Health Coverage, Treichville, 52, boulevard de Marseille, BPV5 Abidjan, Côte d’Ivoire
3Department of Physicochemical and pharmaceutical sciences, Faculty of Health Sciences, Abdou Moumouni University of Niamey, Rive droite, Harobanda10896Niamey, Niger
*Corresponding author. E-mail address: amonkou.cinthia@ufhb.edu.ci (A-N’G. Anne Cinthia)
The Regional Pharmaceutical Plan of ECOWAS (PPRC) was adopted in 2014 by to address the insufficient development of local pharmaceutical industry (IP) with a desired impact to be seen by 2025. We appreciated the level of adequacy of the political and regulatory measures taken in Côte d’Ivoire, one Member State, to implement it. The Government recently identifies the PI cluster among the three priority since the five-year term 2021-2025. Various plans, but only a specific one, exist in Côte d’Ivoire in line with the desired industrialization. As for the specific legal framework, it hasn’t undergone much change since 2014. Nevertheless, in terms of institutional governance, a service dedicated to its promotion has been created into the Ministry of Health by Ministerial Order in April 2025.
There is a certain adequation between policies, regulatory and PPRC as well as good perspectives. That must be optimized in a global industrialization plan and the adoption of texts allowing it.
Pharmaceutical industry, Regulations, Political support, Côte d’Ivoire, West Africa, ECOWAS, Pharmaceutical Manufacturing Plan for Africa (PMPA), PPRC
